

Supplementary Materials:

The survey is attached as supplemental file. We also provide the basis of our statistical assessment as shown in supplemental table S1.

Supplemental Table S1: Summary of the case reports.

Case	Grading	Ki-67	Therapy line	Comment
C1	G2	<5%	2nd	PD under 1 st -line SSA, comorbidities
C2	G2	<10%	1st	Asymptomatic, not resectable liver metastases
C3	G2	8%	2nd	PD under SSA after 12 months
C4	G2	<10%	3rd	PD after 10 months CTx (last 4 months CTx-free), prior SSA
C5	G1	1%	2nd	PD under 1 st -line SSA for 3 years
C6	G2	15%	1st	Tumor-specific symptoms
C7	G2	15%	2nd	PD under 1 st -line CTx, primary resected
C8	G2	20%	1st	Liver only metastasized, primary tumor in the tail of the pancreas
C9	G2	5%	3rd	PD under PRRT (4 cycles) after 1 year, prior SSA
C10	G1	1%	curative	3cm in size, no growth dynamic, no metastasis
C11	G2	5%	curative	3cm pancreatic primary; single liver metastasis (4 cm)
C12	G2	20%	2nd	PD under CTx, tumor specific symptoms, liver only disease
C13	G3	35%	2nd	CTx not tolerated and PD after 8 weeks
C14	G2	15%	1st	Declines CTx, elevated liver enzymes

PD, progressive disease; CTx, chemotherapy; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analogues.

Supplemental Table S2: Subgroup analysis based on the different disciplines participating.

	G1/2 Ki-67 <10%								G2 Ki-67 >10%						G3	
	C2	C1	C3	C5	C4	C9			C6	C8	C14	C7	C12	C13		
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Endocrinology (n=18)																
SSA	13	72%			3	17%			1	6%	1	6%	3	17%	1	6%
PRRT	1	6%	13	72%	9	50%	10	56%	2	11%	1	6%	11	61%	9	50%
Chemotherapy	1	6%	4	22%	8	44%			1	6%	5	28%			3	17%
TKI			1	6%	1	6%			2	11%	8	44%			1	6%
TACE/SIRT					3	17%	4	22%					2	11%		
Resection																
OTH	3	17%			1	6%	1	6%	1	6%	1	6%			1	6%
Gastroenterology (n=13)																
SSA	10	77%			1	8%							1	8%		
PRRT			6	46%	2	15%	6	46%	2	15%	1	8%			3	23%
Chemotherapy	1	8%	2	15%	7	54%	1	8%	8	62%	7	54%			9	69%
TKI			2	15%	2	15%	1	8%	1	8%	4	31%	1	8%		
TACE/SIRT	1	8%					4	31%	1	8%						
Resection													3	23%		
OTH	1	8%	3	23%	1	8%	1	8%	1	8%	1	8%	2	15%	1	8%
Nuclear medicine (n=20)																
SSA	14	70%			3	15%			3	15%	1	5%	1	5%		
PRRT	1	5%	16	80%	13	65%	12	60%	13	65%	1	5%	3	15%	10	50%
Chemotherapy	1	5%	2	10%	5	25%			9	45%	7	35%	1	5%	3	15%
TKI			1	5%	1	5%			1	5%			1	5%	3	15%
TACE/SIRT					4	20%	2	10%							10	50%
Resection									2	10%	5	25%				
OTH	4	20%	1	5%	1	5%	1	5%	2	10%	2	10%	1	5%	1	5%
Oncology (n=16)																
SSA	16	100%			1	6%			1	6%	1	6%	3	19%		
PRRT			8	50%	6	38%	11	69%	4	25%			11	69%	7	44%
Chemotherapy			2	13%	3	19%			9	56%	5	31%			7	44%
TKI			5	31%	5	31%	1	6%	2	13%	10	63%				
TACE/SIRT					2	13%										
Resection									1	6%	1	6%			1	6%
OTH			1	6%	2	13%	1	6%	1	6%	1	6%			2	13%